LEARNING POINTS/TAKE HOME
MESSAGES
We hope readers can appreciate that cPAN is a distinct entity different
to sPAN, with a more benign clinical course. The risk of progression
from cPAN to sPAN remains unclear, albeit slow. Prompt recognition of
this rare condition is required to prevent permanent neurological
deficit and scarring. In terms of management, cPAN is steroid responsive
and steroid sparing agents are effective to prevent relapse.